In one aspect, the present invention provides a composition and a kit
comprising a combination of topoisomerase inhibitor and PARP inhibitor
for treatment of cancer. In another aspect, the invention provides a
method of treating cancer comprising administering to a subject a
combination of topoisomerase inhibitor and PARP inhibitor. In particular,
the invention provides compositions and methods for treating cancer in a
subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase,
as well as providing formulations and modes of administering such
compositions.